New Study for Head and Neck Cancers

The Mouth Cancer Foundation is supporting a new study looking at the type of light treatment with chemotherapy for head neck cancer patients as it may be a lifeline for those whose cancer returns.

This study, which has been approved by the hospital’s independent ethics committee and the national regulatory authorities, is being carried out by PCI Biotech and Cancer Research UK. It is looking at a new cancer treatment called PCA11and will investigate how well a combination of laser light treatment and a chemotherapy drug called bleomycin works to treat people with head and neck cancer.

With this treatment patients have 2 drugs.  The first is called Amphinex, which makes body tissue sensitive to light. The second is bleomycin chemotherapy. After you have had Amphinex and bleomycin, the doctor directs a laser light either onto the surface of the cancer, or through fibres that are put directly into the cancer. The light activates the Amphinex, which in turn helps the bleomycin to get into the cancer cells and kill them.

Patients usually require several treatments of bleomycin. But researchers hope that the study will prove only one dose is required. The aim of this study is to see if this treatment works and if it will be a safe choice for people with head and neck cancers that have come back after previous treatment.

For full details of the study and conditions of taking part please visit